Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T17:33:43.493Z.
Calculation as of: 2026-10-06T17:33:43.493Z.
Quote observation: 2026-10-06T17:29:48.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 954f90b5803147d7e77bb33cb230df589f2ac0b2215919e8afc4fbf9605c1a4a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$222.66M
Price/OCF Ratio
N/A
TTM Avg
9.04
3Y Avg
9.10
5Y Avg
9.10
Market Cap
$216.82M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$213.84M
Price/OCF Ratio
35.95
TTM Avg
45.91
3Y Avg
60.75
5Y Avg
60.42
Market Cap
$230.97M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Profound Medical Corp. (PROF) | $222.75M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $222.66M | N/A | 9.04 | 9.10 | 9.10 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $216.82M | N/A | N/A | N/A | N/A |
| BioAge Labs Inc. (BIOA)vs › | $229.10M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $230.16M | N/A | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $231.05M | N/A | 62.49 | 62.49 | 62.49 |
| Niagen Bioscience Inc (NAGE)vs › | $213.84M | 35.95 | 45.91 | 60.75 | 60.42 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $212.39M | N/A | N/A | N/A | N/A |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $230.97M | N/A | N/A | N/A | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $211.22M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
